Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1292519/000155837023018294/nviv-20230930x10q.htm
SEC Filings
NVIV Annual Reports
10-K Annual Report March 2023
10-K Annual Report March 2022
10-K Annual Report March 2021
10-K Annual Report February 2020
10-K Annual Report April 2019
10-K Annual Report March 2018
10-K Annual Report March 2017
10-K Annual Report March 2016
10-K Annual Report March 2015
10-K Annual Report March 2014
10-K Annual Report March 2023
10-K Annual Report March 2022
10-K Annual Report March 2021
10-K Annual Report February 2020
10-K Annual Report April 2019
10-K Annual Report March 2018
10-K Annual Report March 2017
10-K Annual Report March 2016
10-K Annual Report March 2015
10-K Annual Report March 2014
NVIV Quarterly Reports
NVIV Corporate News
Listing Status February 2024
Bankruptcy or Receivership February 2024
Vote of Security Holders January 2024
Listing Status December 2023
Shareholder Nomination November 2023
Event for Officers November 2023
Ending Agreement September 2023
Financial Exhibit
Other Events March 2023
Event for Officers
Financial Exhibit November 2022
Financial Exhibit
New Agreement
Unregistered Sales October 2022
Listing Status
February 2024
Bankruptcy or Receivership
February 2024
Vote of Security Holders
January 2024
Listing Status
December 2023
Shareholder Nomination
November 2023
Event for Officers
November 2023
Ending Agreement
September 2023
Financial Exhibit
Other Events
Other Events
March 2023
Event for Officers
Financial Exhibit
Financial Exhibit
November 2022
Financial Exhibit
New Agreement
Unregistered Sales
New Agreement
Unregistered Sales
October 2022
Last10K.com | 10-Q Quarterly Report Wed Nov 08 2023
Document and Entity Information - shares | 9 Months Ended | |
|---|---|---|
Sep. 30, 2023 | Nov. 03, 2023 | |
| Document Information [Line Items] | ||
| Document Type | 10-Q | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Entity Incorporation, State or Country Code | NV | |
| Entity Address, Address Line One | 1500 District Avenue | |
| Entity Address, City or Town | Burlington | |
| Entity Address, State or Province | MA | |
| Document Period End Date | Sep. 30, 2023 | |
| Entity Registrant Name | InVivo Therapeutics Holdings Corp. | |
| Title of 12(b) Security | Common Stock | |
| Trading Symbol | NVIV | |
| Security Exchange Name | NASDAQ | |
| Entity Current Reporting Status | Yes | |
| Entity Interactive Data Current | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | false | |
| Entity Shell Company | false | |
| Entity Common Stock, Shares Outstanding | 3,105,446 | |
| Entity File Number | 001-37350 | |
| Entity Tax Identification Number | 36-4528166 | |
| Entity Address, Postal Zip Code | 01803 | |
| Local Phone Number | 863-5500 | |
| City Area Code | 617 | |
| Entity Central Index Key | 0001292519 | |
| Current Fiscal Year End Date | --12-31 | |
| Document Fiscal Year Focus | 2023 | |
| Document Fiscal Period Focus | Q3 | |
| Amendment Flag | false | |
| Former Address [Member] | ||
| Document Information [Line Items] | ||
| Entity Address, Address Line One | One Kendall Square | |
| Entity Address, Address Line Two | Suite B14402 | |
| Entity Address, City or Town | Cambridge | |
| Entity Address, State or Province | MA | |
| Entity Address, Postal Zip Code | 02139 |
View differences made from one quarter to another to evaluate Invivo Therapeutics Holdings Corp.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Invivo Therapeutics Holdings Corp..
Assess how Invivo Therapeutics Holdings Corp.'s management team is paid from their Annual Proxy
Invivo Therapeutics Holdings Corp.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Rating
Learn More
Filter Sentiment:
Filter Category:
Filter Subcategory:
-
Financial - Expense Highlight
We have limited liquidity and capital resources and anticipate that we will continue to incur significant expenses and operating losses as we implement our review of strategic options, and we may incur increased expenses if and to the extent we are unable to stop activities or eliminate expenses related to the Neuro-Spinal Scaffold program on our anticipated timelines or we incur unexpected material expenses during this process; need to respond to any investigations or inquiries, or defend against any litigation, that may result from the announcement of the results of our INSPIRE 2.0 Study; are unable to successfully complete our exploration and evaluation of strategic options and implement any such options; or are unable to limit our ongoing operating costs as we work to explore and evaluate strategic options.
-
Other - Other Highlight
These forward-looking statements are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements in this Quarterly Report, including factors such as our ability to raise substantial additional capital to finance our planned operations and to continue as a going concern; our ability to execute our strategy and business plan; our ability to identify and execute on potential strategic alternatives that we are currently exploring; our ability to retain management and other key personnel; and other factors detailed under "Risk Factors" in Part II, Item 1A of this Quarterly Report.
-
Financial - Expense Highlight
Research and development expenses for the three months ended September 30, 2023 were $0.7 million, a decrease of $0.5 million compared to the three months ended September 30, 2022.
-
Financial - Expense Highlight
Research and development expenses for the nine months ended September 30, 2023 were $2.8 million, a decrease of $1.1 million compared to the nine months ended September 30, 2022.
-
Financial - Expense Highlight
The decrease in research and development expenses for the nine months ended September 30, 2023 is mainly attributable to a $0.7 million decrease in compensation related expense as result of cost cutting measures taken in the 20 manufacturing and quality areas in response to the negative topline data from the INSPIRE 2.0 Study, and a $0.4 million decrease in clinical trial costs as the INSPIRE 2.0 Study reached full enrollment in the prior year.
-
Other - Other
In August 2023, we entered...Read more
-
Other - Other
There can be no assurance...Read more
-
Other - Other
There can be no assurance...Read more
-
Financial - Expense
General and administrative expenses for...Read more
-
Financial - Expense
General and administrative expenses for...Read more
-
Financial - Expense
The change in cash from...Read more
-
Other - Other
The going concern assumption contemplates...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Stockholders' Equity
Consolidated Statements Of Changes In Stockholders' Equity (Parenthetical)
Consolidated Statements Of Operations
Accrued Expenses
Accrued Expenses (Details)
Accrued Expenses (Tables)
Cash And Cash Equivalents
Cash And Cash Equivalents (Details)
Cash And Cash Equivalents (Tables)
Cash And Cash Equivalents - Cash, Cash Equivalents, And Restricted Cash (Details)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Compensation (Details)
Commitments And Contingencies - Lease Classification (Details)
Commitments And Contingencies - Lease Expenses (Details)
Commitments And Contingencies - Lease Other Information (Details)
Commitments And Contingencies - Leases (Details)
Commitments And Contingencies - Maturities Of Lease Liabilities (Details)
Employee Benefit Plan
Employee Benefit Plan (Details)
Fair Values Of Assets And Liabilities
Fair Values Of Assets And Liabilities (Details)
Fair Values Of Assets And Liabilities (Tables)
Fixed Assets
Fixed Assets (Details)
Fixed Assets (Tables)
Fixed Assets - Depreciation (Details)
Income Taxes
Income Taxes (Details)
Nature Of Operations And Going Concern, Basis Of Presentation And Recent Accounting Pronouncements
Nature Of Operations And Going Concern, Basis Of Presentation And Recent Accounting Pronouncements (Policies)
Nature Of Operations And Going Concern, Basis Of Presentation And Recent Accounting Pronouncements - Reverse Stock Split (Details)
Net Loss Per Common Share
Net Loss Per Common Share (Details)
Net Loss Per Common Share (Tables)
Restricted Cash
Restricted Cash (Details)
Stock-Based Compensation
Stock-Based Compensation (Details)
Stock-Based Compensation (Tables)
Stock-Based Compensation - Share-Based Compensation (Details)
Stock-Based Compensation - Summary Of Option Activity - (Details)
Stockholders Equity
Stockholders Equity - Authorized (Details)
Stockholders Equity - Common Stock Transaction (Details)
Warrants
Warrants (Details)
Warrants (Tables)
Material Contracts, Statements, Certifications & more
Invivo Therapeutics Holdings Corp. provided additional information to their SEC Filing as exhibits
Ticker: NVIV
CIK: 1292519
Form Type: 10-Q Quarterly Report
Accession Number: 0001558370-23-018294
Submitted to the SEC: Wed Nov 08 2023 4:31:02 PM EST
Accepted by the SEC: Wed Nov 08 2023
Period: Saturday, September 30, 2023
Industry: Surgical And Medical Instruments And Apparatus
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/nviv/0001558370-23-018294.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...